Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| ONC | CLUSTER | bearish | 5/10 | Director Wang Xiaodong executed a large derivative exercise of 434,392 shares (31,028 at $36.9 + 403,364 at $0) and simu | Oct 2, 2026 |
| SBFM | S-1 | bearish | 6/10 | Sunshine Biopharma Inc. filed an S-1 registration statement for a best-efforts offering of up to 10,180,337 Common Units | Oct 2, 2026 |
| TANH | 6-K | neutral | 2/10 | Tantech Holdings Ltd reported the resignation of Chairman and Director Yefang Zhang effective October 1, 2026, with no d | Oct 2, 2026 |
| QNRX | DEF 14A | neutral | 4/10 | Quoin Pharmaceuticals is holding a special shareholder meeting on November 12, 2026, to vote on two proposals: (1) amend | Oct 2, 2026 |
| LEEEF | 8-K | neutral | 3/10 | Leef Brands appointed Hirsh Jain as an independent director, expanding the board to six members, while CFO Kevin Wilson | Oct 2, 2026 |
| SILO | 8-K | neutral | 4/10 | Silo Pharma acquired software, technology, and related intellectual property (the 'Klone' brand web-based tools) from No | Oct 2, 2026 |
| UTHR | CLUSTER | neutral | 3/10 | CEO Martine Rothblatt and EVP Paul Mahon sold a combined $559K in open-market shares over two days, following derivative | Oct 2, 2026 |
| HCWB | S-1 | bearish | 5/10 | HCW Biologics filed an S-1 registration statement to register the resale of up to 1,807,228 shares of common stock by Ar | Oct 2, 2026 |
| CING | 8-K | neutral | 3/10 | Cingulate Inc. filed an 8-K to disclose an amendment to the employment agreement of its Chief Medical Officer, Matthew N | Oct 2, 2026 |
| BYSI | 8-K | bearish | 8/10 | BeyondSpring received a Nasdaq deficiency notice on September 29, 2026, for failing to maintain a minimum $35 million ma | Oct 2, 2026 |
| OLMA | PRESS-RELEASE | neutral | 2/10 | Olema Oncology granted inducement stock options for 235,950 shares to six new employees at $8.27/share, vesting over fou | Oct 2, 2026 |
| IKT | PRESS-RELEASE | neutral | 2/10 | Inhibikase Therapeutics granted 128,000 non-qualified stock options to two newly-hired non-executive employees as an ind | Oct 2, 2026 |
| NTLA | PRESS-RELEASE | neutral | 2/10 | Intellia Therapeutics granted inducement stock awards to eight new employees under its 2024 Inducement Plan. This is a r | Oct 2, 2026 |
| KZIA | SC 13G/A | bullish | 5/10 | Dauntless Investment Group, LLC filed a Schedule 13G/A disclosing a new 5.42% passive stake in Kazia Therapeutics, holdi | Oct 2, 2026 |
| GNTA | SC 13D/A | neutral | 4/10 | This Amendment No. 1 to Schedule 13D reports a decrease in the group's beneficial ownership percentage from 11.50% to 11 | Oct 2, 2026 |
| GMAB | 6-K | neutral | 3/10 | Genmab A/S filed a 6-K reporting that Darwin Global Management Limited has disclosed a 5.11% voting stake in the company | Oct 2, 2026 |
| CATX | PRESS-RELEASE | neutral | 3/10 | Perspective Therapeutics announced that data from its lapemelanotide zapixetar ([²¹²Pb]VMT01) program for metastatic mel | Oct 2, 2026 |
| CUVL | 6-K | neutral | 2/10 | Clinuvel Pharmaceuticals filed a Form 6-K with the SEC on October 2, 2026, to report that it had filed its Notice of Ann | Oct 2, 2026 |
| BIIB | PRESS-RELEASE | bullish | 6/10 | Biogen announced positive 52-week Phase 2 data for litifilimab in cutaneous lupus erythematosus (CLE), showing continued | Oct 2, 2026 |
| EIKN | SC 13G/A | neutral | 3/10 | Abu Dhabi Investment Authority (ADIA) filed an amended Schedule 13G disclosing a passive 2.1% stake in Eikon Therapeutic | Oct 2, 2026 |
| XBIT | DEF 14A | bearish | 5/10 | XBiotech's 2026 definitive proxy statement schedules a virtual annual meeting for November 24, 2026, with three proposal | Oct 2, 2026 |
| ABT | ANALYST-UPGRADE | bullish | 5/10 | Rothschild& Co double-upgraded Abbott Laboratories (ABT) from Neutral to Buy on October 2, 2026, raising its price targe | Oct 2, 2026 |
| EVAX | 6-K | neutral | 5/10 | Evaxion announced it will present new immune data from the Phase 2 trial of its personalized cancer vaccine EVX-01 at th | Oct 2, 2026 |
| INKT | PRESS-RELEASE | neutral | 4/10 | MiNK Therapeutics presented preclinical data at SITC 2026 showing agenT-797 enables tumor-cell killing in a checkpoint i | Oct 2, 2026 |
| IMRX | PRESS-RELEASE | neutral | 3/10 | Immuneering announced a poster presentation at SITC 2026 showing that atebimetinib enhances PD-1 checkpoint blockade in | Oct 2, 2026 |
| EVAX | PRESS-RELEASE | neutral | 4/10 | Evaxion announced new immune data from its phase 2 trial of personalized cancer vaccine EVX-01 in advanced melanoma will | Oct 2, 2026 |
| PYXS | SC 13G/A | neutral | 4/10 | GordonMD Global Investments LP and related entities filed an amended Schedule 13G disclosing beneficial ownership of 27, | Oct 2, 2026 |
| IPSC | 8-K | neutral | 4/10 | Century Therapeutics presented nonclinical data for CNTY-813, its iPSC-derived islet replacement therapy for type 1 diab | Oct 2, 2026 |
| SRZN | 8-K | bullish | 7/10 | Surrozen received FDA clearance of its IND application for SZN-8141, a bifunctional Wnt agonist/VEGF antagonist antibody | Oct 2, 2026 |
| HYPD | 8-K | bullish | 6/10 | Hyperion DeFi repaid ~$8.6M in legacy debt to Avenue Capital, eliminating all long-term debt, and repurchased 240,124 sh | Oct 2, 2026 |